43 results
DEF 14A
NMRA
Neumora Therapeutics Inc.
25 Apr 24
Definitive proxy
4:05pm
Strategy Officer at AbbVie, a public pharmaceutical company, where he was responsible for AbbVie’s corporate strategy, business development … through February 2022, Mr. Piacquad served as Senior Vice President, Business Development of Amgen where he was responsible for corporate strategy
10-K
2023 FY
EX-97.1
NMRA
Neumora Therapeutics Inc.
7 Mar 24
Annual report
4:05pm
.
“Committee” means the committee of the Board responsible for executive compensation decisions comprised solely of independent directors (as determined under
10-K
crh 620x07v15l
7 Mar 24
Annual report
4:05pm
10-K
EX-31.2
xf4vtnb mqm3a0llmf
7 Mar 24
Annual report
4:05pm
10-K
EX-31.1
3atwhm162em7 u0g
7 Mar 24
Annual report
4:05pm
10-Q
EX-31.2
6hxtft34z4j4c2kj
1 Nov 23
Quarterly report
4:05pm
10-Q
EX-31.1
uor1 ev8yuugy9
1 Nov 23
Quarterly report
4:05pm
S-8
EX-99.3
fd9yjes 8luc
19 Sep 23
Registration of securities for employees
9:57pm
S-8
EX-99.1
4bzpl vm3j6aa7hs1z
19 Sep 23
Registration of securities for employees
9:57pm
8-K
EX-3.2
gat 1vi4l
19 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:16pm
424B4
0cq6crq
18 Sep 23
Prospectus supplement with pricing info
4:12pm
S-1/A
de13h
11 Sep 23
IPO registration (amended)
6:07am
S-1/A
EX-1.1
eutefbap58
11 Sep 23
IPO registration (amended)
6:07am
S-1
EX-10.7
sk4gy nmzn20nm
25 Aug 23
IPO registration
5:03pm
S-1
EX-3.4
20ewft0 7fw
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.2
uv5ovia9
25 Aug 23
IPO registration
5:03pm
S-1
EX-10.18
xu8xvh
25 Aug 23
IPO registration
5:03pm